Related Experiment Videos
[Clinical evaluation of a new parenteral cephem, cefozopran, in children]
S Taniuchi1, H Higashino, J Takaya
1Department of Pediatrics, Kansai Medical University.
Insights
Cefozopran (CZOP) demonstrated good clinical efficacy in pediatric patients with bacterial infections, showing excellent or good results in most cases. Its antibacterial activity was comparable to ceftazidime with minimal side effects.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Background:
- Cefozopran (CZOP) is a novel parenteral cephem antibiotic.
- Evaluation of antibacterial activity and clinical efficacy is crucial for new antibiotics.
Purpose of the Study:
- To assess the antibacterial activity and clinical efficacy of Cefozopran (CZOP) in pediatric patients.
- To compare the efficacy and safety of CZOP with ceftazidime.
Main Methods:
- CZOP was administered to 11 pediatric patients at doses of 24.0-78.0 mg/kg/day in three divided doses via 30-minute drip infusion.
- Nine patients with acute pneumonia, urinary tract infections, lymphadenitis, and sepsis were clinically evaluated.
- Minimum Inhibitory Concentrations (MICs) of CZOP were determined and compared to ceftazidime.
Main Results:
- Clinical efficacy was excellent in 5 patients, good in 3, and fair in 1.
- Bacteriological eradication was achieved in 4 out of 5 confirmed bacterial strains.
- MICs of CZOP were found to be equivalent to those of ceftazidime.
- Adverse events were observed in 3 patients (diarrhea, elevated GPT, thrombocytosis) but were not significant.
Conclusions:
- Cefozopran (CZOP) exhibits significant clinical efficacy and favorable bacteriological response in pediatric patients.
- CZOP demonstrates comparable antibacterial activity to ceftazidime.
- The safety profile of CZOP in this pediatric cohort was acceptable with no significant adverse events.
Abstract:
Cefozopran (CZOP, SCE-2787), a new parenteral cephem, was evaluated for its antibacterial activity and clinical efficacy. CZOP, 24.0-78.0 mg/kg/day, was given to 11 pediatric patients in 3 dose a day via 30-minute drip infusion. Clinically evaluated were nine patients including 4 with acute pneumonia, 2 with urinary tract infections, 2 with lymphadenitis and 1 with sepsis. Two patients were excluded because of possible non-bacterial infections. Clinical efficacies were excellent in 5, good in 3 and fair in 1. Bacteriological responses were confirmed for 5 strains in 5 patients. Four strains were eradicated, but one strain was not. MICs of CZOP were equal to those of ceftazidime. Side effects or abnormal laboratory test results were observed in 3 patients; diarrhea in 1, elevated GPT in 1 and thrombocytosis in 1, but none of them was significant.